Number of Positive Lymph Nodes Is Superior to LNR and LODDS for Predicting the Prognosis of Pancreatic Neuroendocrine Neoplasms

Bingqiang Gao†, Dongkai Zhou†, Xiaohui Qian†, Yuancong Jiang†, Zhenghao Liu†, Wang Zhang† and Weilin Wang†,2,3,4,5*

1 Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 2 Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, China, 3 Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou, China, 4 Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou, China, 5 Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, China

Background: The American Joint Committee on Cancer (AJCC) staging for pancreatic neuroendocrine neoplasms (PanNENs) based on the number of positive lymph nodes (PLNs) is the most widely accepted nodal staging system. New nodal staging schemes that take both the number of PLNs and the number of examined lymph nodes into consideration have emerged as useful prognostic tools. The aim of the current study was to determine the most effective nodal staging system, among the 8th edition AJCC N staging (or PLN staging), lymph node ratio (LNR), and log odds of positive lymph nodes (LODDS), for predicting the cause-specific survival of patients with PanNENs.

Methods: The clinicopathological and prognostic data of 2,295 patients from the Surveillance, Epidemiology, and End Results (SEER) database, diagnosed with PanNENs between 1988 and 2015, were reviewed retrospectively.

Results: A multivariate analysis identified PLN and LNR staging as independent prognostic factors, but not LODDS. The PLN staging exhibited higher C-index and area under the curve values than those of the LNR and LODDS, indicating better predictive discriminatory capacity. No significant difference in the survival of patients was observed within the same PLN staging subgroup according to the number (high or low) of examined lymph nodes. In contrast, intra-group heterogeneity was seen with use of LNR and LODDS staging, due to overestimation of the risk of insufficient examined lymph nodes, and LODDS failed to stratify patients without lymph nodes metastasis into different risk groups.

Conclusions: The PLN staging is more reliable than LNR and LODDS staging for predicting the cause-specific survival of PanNENs.

Keywords: pancreatic neuroendocrine neoplasms, log odds of positive lymph nodes, lymph node ratio, number of positive lymph nodes, staging
INTRODUCTION

Pancreatic neuroendocrine neoplasms (PanNENs) are malignancies arising from the pancreas showing neuroendocrine differentiation (1). Their incidence has significantly increased over the past few decades, probably due to advancements in imaging techniques (2, 3). PanNENs exhibit heterogeneous biological behavior, and include indolent and aggressive types. Based on differences in the mitotic count and Ki-67 labeling index, PanNENs can be divided into well-differentiated pancreatic neuroendocrine tumors (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs) (1). In the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, the nodal staging system for PanNETs is based only on nodal status (negative or positive), while the system for PanNECs is based on the number of positive lymph nodes (PLNs) (4). Although it is challenging to stratify patients into different risk groups due to the rarity and heterogeneity of PanNENs, a unified staging scheme is more attractive in clinical application. Partelli et al. reported that the number of PLNs accurately predicts recurrence not only for PanNECs but also for PanNETs (5). New nodal staging schemes that take both the number of PLNs and the number of examined lymph nodes (or positive lymph nodes) into consideration have emerged as useful prognostic tools. The lymph node ratio (LNR) is defined as the ratio between the number of PLNs and the total number of examined lymph nodes. The LNR is increasingly recognized as a strong predictor of survival in patients with other pancreatic neoplasms, including pancreatic adenocarcinoma (6) and intraductal papillary mucinous neoplasms (7). Previously, it was reported that an LNR-based staging system is superior to the current 8th edition AJCC staging system for PanNETs (8). Log odds of positive lymph nodes (LODDS) is defined as log(PLNs+0.5)/(examined lymph nodes-PLNs+0.5). Adding 0.5 to the numerator and denominator avoids division by zero, which aids in stratification of patients without PLNs into different prognostic groups (9). Recently, LODDS staging was thought a better predictor of survival in the small bowel neuroendocrine tumors compared with LNR and PLN staging (10). However, the actual prognostic value of LODDS in PanNENs remains unclear. Therefore, the aim of the current study was to determine the most appropriate nodal staging system for predicting cause-specific survival in PanNENs, by evaluating the prognostic ability of the PLN (or 8th edition AJCC N staging), LNR, and LODDS staging systems.

MATERIALS AND METHODS

The data of patients with PanNENs during the period 1988 to 2015 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The following histological subtypes were included in the analysis, based on their International Classification of Diseases for Oncology, Third Edition codes: islet-cell adenocarcinoma (8150), malignant beta-cell tumor (8151), malignant alpha-cell tumor (8152), G-cell tumor (8153), mixed islet cell and exocrine tumor (8154), VIPoma (8155), malignant somatostatinoma (8156), carcinoid tumor (8240), enterochromaffin cell tumor(8241), goblet carcinoid tumor (8243), mixed adenoneuroendocrine carcinoma (8244), neuroendocrine carcinoid (8246), and atypical carcinoid tumor (8249).

The patient eligibility criteria were as follows: (1) histologically confirmed neuroendocrine tumors; (2) primary tumor located in the pancreas; (3) no other malignant tumors; (4) ≥18 years of age; (5) treatment by primary site surgery; (6) at least one lymph node was examined; (7) complete PLN data; (8) survival time of more than 0 months; and (9) close follow-up. In this study, the primary outcome was cause-specific survival, defined as death caused by PanNENs.

Scatterplots and Spearman’s correlation coefficients were used to evaluate the distributions of, and correlations among, continuous PLN, LNR, and LODDS variables. Smooth curves from restricted cubic spline were plotted to assess the non-linear relationship between three nodal staging systems and log hazard ratio (HR) by univariate Cox regression model (11). X-tile software (version 3.6.1; https://medicine.yale.edu/lab/rimm/research/software/) was used to determine the optimal cutoff points for the PLN, LNR, and LODDS staging systems. This software divides patients into two or three groups based on the χ² value. Cross-validation was performed to derive corrected P-values (12). The discriminative efficacy of the different nodal staging systems was assessed by Harrell’s concordance index (C-index), which ranges from 0.5 (no predictive power) to 1 (complete differentiation) (13). Because the survival rate of the patients changed with time, we also used time-dependent area under the receiver operating characteristic curve (AUC) analysis to examine the discriminative abilities of the different nodal staging systems over a 10-year period (14). Univariate and multivariate analyses were performed to evaluate the prognostic performance of the three nodal staging systems and other possible prognostic factors. All factors with a P-value <0.2 in the univariate analysis were included in Cox proportional hazards multivariate models. Cases with missing data were excluded from the multivariate analysis.

All analyses were conducted using X-tile (version 3.6.1; Yale University School of Medicine, New Haven, CT, USA), SPSS (version 22.0; SPSS Inc., Chicago, IL, USA), and R software (version 3.5.3; R Foundation for Statistical Computing, Vienna, Austria). A P-value <0.05 was considered significant, and all tests were two-tailed.

RESULTS

Characteristics of Patients

A total of 2,295 patients with PanNENs who met the inclusion criteria were enrolled in this study (Figure 1); their clinical characteristics are described in Table 1. The study population was 78.7% white, 12.0% black, and 9.3% other races. About 53% of the patients were male and 47% were female. The median age
at diagnosis was 57 years. About 90.0% of patients underwent a local or partial pancreatectomy. Most tumors were located in the tail of the pancreas (40.2%) or the head of the pancreas (34.4%). The vast majority of tumors were non-functioning (97.4%) and well-to moderately differentiated on histological examination (91.6%). The results of the univariate analysis showed that age, sex, marriage, extent of resection, histologic grade, T staging, M staging, and the number of examined lymph nodes had significant prognostic value (P < 0.05).

Characteristics of Three Nodal Staging Schemes

Scatterplots (Figure 2) were created to assess the relationships of PLN, LNR, and LODDS data. Each PLN value could be divided into different LNR and LODDS values. Each LODDS value had a one-to-one correspondence with an LNR value, except when LNR equaled 0 or 1. The LODDS data were more strongly correlated with the LNR than PLN data (r = 0.752 vs. r = 0.703).

Restricted cubic splines (Figure 3) were used to assess the relationships between the three lymph node staging systems and log HR. A nonlinear association was found, and the mortality risk increased as the LODDS, LNR, and PLN values increased in all patients with PanNENs. Figure 3D showed that the confidence interval (CI) included 0, suggesting that LODDS was neither a risk factor nor a protective factor in node-negative patients.

Three-Category Nodal Staging Schemes

To compare the three lymph node staging schemes from three-category perspective, the continuous variables of the PLN, LNR, and LODDS were divided into three groups using X-Tile software. The PLN staging system includes three groups: PLN1 (≤0), n = 1,425 (62.1%); PLN2 (1–3), n = 570 (24.8%); and PLN3 (≥4), n = 300 (13.1%). It happens to coincide with the 8th edition AJCC N staging for the PanNECs. The LNR also yielded three risk groups: LNR1 (≤0), n = 1,425 (62.1%); LNR2 (0–0.28), n = 474 (20.7%); and LNR3 (>0.28), n = 396 (17.3%). Finally, the LODDS staging consisted of the following three groups: LODDS1 (≤−2.56), n = 961 (41.9%); LODDS2 (−2.56 to −0.66), n = 968 (42.2%); and LODDS3 (>−0.66), n = 366 (15.9%) (Table 2).

The results of the univariate analysis showed that the three-category PLN, LNR, and LODDS staging systems all had significant prognostic value. However, in the multivariate analysis, only PLN and LNR staging were independent prognostic factors of a worse survival (Table 2).

Based on the C-index value, PLN staging (0.642; 95% CI: 0.611–0.673) had higher prognostic value compared with LNR...
TABLE 1 | Clinicopathologic characteristics of patients.

| Characteristic                  | Patients No. (%) | Univariate Analysis |
|--------------------------------|------------------|---------------------|
|                                |                  | HR (95% CI)         | P          |
| Age (years)                    |                  |                     |            |
| ≤60                            | 1,370 (59.7)     | 1 (ref)             | <0.001     |
| >60                            | 925 (40.3)       | 1.700 (1.414–2.045) | 0.032      |
| Sex                            |                  |                     |            |
| Female                         | 1,075 (46.8)     | 1 (ref)             | 0.032      |
| Male                           | 1,220 (53.2)     | 1.224 (1.017–1.473) | 0.007      |
| Marriage                       |                  |                     |            |
| Yes                            | 1,462 (66.9)     | 1 (ref)             | 0.007      |
| No                             | 724 (33.1)       | 1.303 (1.075–1.580) | 0.164      |
| Race                           |                  |                     |            |
| White                          | 1,793 (78.7)     | 1 (ref)             | 0.402      |
| Black                          | 273 (12.0)       | 0.928 (0.691–1.247) | 0.164      |
| Others                         | 211 (9.3)        | 0.798 (0.562–1.134) | 0.016      |
| Tumor location                 |                  |                     |            |
| Head                           | 738 (34.4)       | 1 (ref)             | 0.602      |
| Body                           | 301 (14.0)       | 0.809 (0.584–1.122) | 0.207      |
| Tail                           | 862 (40.2)       | 0.818 (0.654–1.023) | 0.402      |
| Others                         | 245 (11.4)       | 1.087 (0.791–1.416) | 0.007      |
| Extent of resection            |                  |                     |            |
| Local or partial pancreatectomy| 2,035 (90.0)     | 1 (ref)             | <0.001     |
| Total pancreatectomy           | 226 (10.0)       | 1.664 (1.289–2.147) | 0.164      |
| Functionality                  |                  |                     |            |
| Nonfunctioning                 | 2,236 (97.4)     | 1 (ref)             | 0.207      |
| Functioning                    | 59 (2.6)         | 0.701 (0.403–1.218) | 0.164      |
| Histologic grade               |                  |                     |            |
| Well differentiated or moderately differentiated | 1,728 (91.6) | 1 (ref)             | <0.001     |
| Poorly differentiated or undifferentiated | 159 (8.4) | 5.221 (4.081–6.679) | 0.016      |
| T staging*                     |                  |                     |            |
| T1                             | 497 (28.3)       | 1 (ref)             | <0.001     |
| T2                             | 530 (30.2)       | 1.886 (1.197–2.971) | 0.016      |
| T3                             | 475 (27.1)       | 3.370 (2.198–5.165) | 0.016      |
| T4                             | 254 (14.5)       | 6.247 (4.066–9.596) | <0.001     |
| M staging                      |                  |                     |            |
| M0                             | 1,340 (87.3)     | 1 (ref)             | 0.016      |
| M1                             | 196 (12.7)       | 3.355 (2.322–4.847) | 0.164      |
| Number of examined lymph nodes*|                  |                     |            |
| No.                            | 10 (12)          | 1.012 (1.002–1.023) | 0.164      |

* T staging was graded according to the 8th edition AJCC staging system for well-differentiated PanNETs.
* Continuous variable.
No., number of patients; HR, hazard ratio; IQR, interquartile range.
All variables with a P-value <0.2 in the univariate analysis were then included in multivariate analysis.
The bold values means that the P value is less than 0.05.

FIGURE 2 | Distribution characteristics of LODDS and PLN (A), LNR and PLN (B), LODDS and LNR (C).
and LODDS staging (0.617; 95% CI: 0.585–0.648). As shown in Figure 4, PLN staging consistently had higher AUC values at the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10-year follow-ups than LNR or LODDS staging in the survival analysis, suggesting that it was better able to distinguish between the prognosis of patients with PanNENs, consistent with the C-index result.

As shown in Table 3, we then compared the survival rates of patients staged using the PLN, LNR, and LODDS staging systems according to the number of examined lymph nodes. For patients in
each PLN staging subgroup (PLN1, PLN2, and PLN3), the survival was highly homogenous among different groups of examined lymph nodes (all \( P > 0.05 \)). For patients in LNR3, LODDS2, and LODDS3 subgroups, statistical differences in the survival could be observed among different groups of examined lymph nodes (\( P_{\text{LNR3}}^{a} = 0.035, \ P_{\text{LODDS2}}^{a} = 0.001, \ P_{\text{LODDS3}}^{a} = 0.025 \)). To find out why LNR and LODDS systems, rather than PLN, showed intra-group heterogeneity, the prognoses of patients with 1–5, 6–10, 11–15, and 16–20 examined lymph nodes were compared with those with >20 examined lymph nodes in each PLN staging subgroup (PLN1, PLN2, and PLN3), the prognoses of patients with \( \leq 20 \) examined lymph nodes were similar to those of patients with >20 examined lymph nodes (all \( P_{b} > 0.05 \)), suggesting that an insufficient number of examined lymph nodes would not lead to PLN staging migration. By contrast, the ratio lymph nodal staging schemes (LNR and LODDS) overestimated the HR for patients with insufficient number of examined lymph nodes. For example, when the number of examined lymph nodes was between 1 and 5, patients were assigned only to the LODDS2 and LODDS3 subgroups, and not to LODDS1. However, patients with 1–5 examined lymph nodes had a significantly better prognosis than those with >20 examined lymph nodes in the LODDS2 and LODDS3 subgroups (both \( P_{b} < 0.001 \)).

LODDS was said to have an inherent advantage for assessing node-negative patients. However, in our study, node-negative patients were assigned only to LODDS1 and LODDS2, and not to LODDS3. The survival curves of node-negative patients stratified by LODDS staging are plotted in Figure 5. No significant difference was observed in survival probability between the LODDS1 and LODDS2 subgroups (\( P > 0.05 \)), indicating that three-category LODDS staging could not stratify node-negative patients into different risk groups.

### Two-Category Nodal Staging Schemes

We compared the different lymph node staging schemes from the perspective of two categories. Using X-Tile software, two-stage solutions were derived for the PLN, LNR, and LODDS staging systems, as follows. For the PLN staging system, PLN1 (= 0), \( n = 1,425 \) (62.1%); and PLN2 (>0), \( n = 870 \) (37.9%), consistent with the 8th edition AJCC N staging system for the neuroendocrine pancreas. For the LNR staging system, LNR1 (= 0), \( n = 1,425 \) (62.1%); and LNR2 (>0), \( n = 870 \) (37.9%). For the LODDS staging system, LODDS1 (\( \leq -0.93 \)), \( n = 1,869 \) (81.4%); and LODDS2 (>−0.93), \( n = 426 \) (18.6%) (Table 4). Only the PLN and LODDS staging systems are discussed in the following section, as the LNR and PLN systems were not different. The result was similar to that of three-category staging schemes. The two-category PLN and LODDS staging were significantly correlated with prognosis in the univariate analysis. However, only the two-category PLN staging was an independent prognostic factor in the multivariate analysis (Table 4).

![FIGURE 4](image-url) **FIGURE 4** | Time-dependent area under the receiver operating characteristic curve (AUC) in patients with PanNENs for three-category staging schemes.

### TABLE 3 | Survival analysis on the basis of three-category nodal staging schemes according to the number of examined lymph nodes (ELNs).

| No. of ELNs | PLN staging | LNR staging | LODDS staging |
|-------------|-------------|-------------|---------------|
| 1–5 ELNs    | PLN1: 512 169.4 0.424 | LNR1: 512 169.4 0.424 | LODDS1: - - - |
|             | PLN2: 172 125.4 0.660 | LNR2: 43 128.2 0.307 | LODDS2: 555 166.9 <0.001 |
|             | PLN3: 17 116.3 0.148 | LNR3: 146 121.9 0.001 | LODDS3: 146 121.9 <0.001 |
| 6–10 ELNs   | PLN1: 356 168.6 0.650 | LNR1: 356 168.6 0.650 | LODDS1: - - - |
|             | PLN2: 128 146.6 0.822 | LNR2: 87 161.9 0.019 | LODDS2: 101 157.5 <0.001 |
|             | PLN3: 63 122.7 0.068 | LNR3: 110 161.7 0.047 | LODDS3: 90 116.5 0.016 |
| 11–15 ELNs  | PLN1: 249 163.2 0.782 | LNR1: 249 163.2 0.782 | LODDS1: - - - |
|             | PLN2: 105 161.8 0.385 | LNR2: 110 161.7 0.047 | LODDS2: 117 154.4 0.065 |
|             | PLN3: 75 115.4 0.257 | LNR3: 110 161.7 0.047 | LODDS3: 63 118.7 0.094 |
| 16–20 ELNs  | PLN1: 149 166.9 0.731 | LNR1: 149 166.9 0.731 | LODDS1: - - - |
|             | PLN2: 76 93.9 0.943 | LNR2: 90 101.7 0.449 | LODDS2: 87 102.2 0.377 |
|             | PLN3: 54 103.3 0.130 | LNR3: 54 103.3 0.130 | LODDS3: 36 59.8 0.025 |
| >20 ELNs    | PLN1: 159 136.2 0.371 | LNR1: 159 136.2 0.371 | LODDS1: - - - |
|             | PLN2: 89 129.2 0.689 | LNR2: 144 133.8 0.101 | LODDS2: 144 133.8 0.101 |
|             | PLN3: 91 93.9 0.271 | LNR3: 91 93.9 0.271 | LODDS3: 36 59.8 0.025 |

*aComparison of survival among different groups of examined lymph nodes.
\( \text{P}^{a} \)Comparison of survival with group of >20 examined lymph nodes.
No., number of patients; Time, mean cause-specific survival (months).
The bold values mean that the \( P \) value is less than 0.05.
As measured by Harrell’s C-index, PLN staging (0.623; 95% CI: 0.595–0.651) had better discriminatory capacity than LODDS staging (0.591; 95% CI: 0.564–0.619). As shown in Figure 6, PLN staging had higher 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10-year AUC values than LODDS staging.

We compared the survival rates of patients using the PLN and LODDS staging systems according to the number of examined lymph nodes. As shown in Table 5, for patients in each PLN staging subgroup (PLN1 and PLN2), the survival was highly homogenous among different groups of examined lymph nodes (P_{PLN1} = 0.371, P_{PLN2} = 0.249). However, significant differences in survival were observed in the LODDS1 and LODDS2 subgroups (P_{LODDS1} = 0.013, P_{LODDS2} = 0.008), indicating that LODDS staging had increased intra-group heterogeneity compared with PLN staging.

Patients were assigned only to the LODDS1 subgroup when the number of PLNs was zero. Therefore, the two-category LODDS staging failed to stratify node-negative patients into distinct survival groups.

**DISCUSSION**

Lymph node metastasis was thought to be an independent predictor of poor outcomes in patients with PanNENs (15, 16). AJCC staging based on the number of PLNs is the most widely accepted nodal staging system. The staging algorithm for PanNENs is the same as that for pancreatic carcinomas in the 7th edition AJCC cancer staging manual (17). A large retrospective cohort study reported that European Neuroendocrine Tumor Society (ENETS) system, which was specifically designed for staging PanNENs, better distinguishes among stages and has higher predictive ability than the 7th

| TABLE 4 | Univariate and multivariate analysis of two-category nodal staging schemes. |
| --- | --- | --- | --- |
| Characteristic | Patients No. (%) | Univariate | Multivariate |
| | | HR (95% CI) | P | HR (95% CI) | P^a |
| PLN staging | | | | |
| PLN0 (=0) | 1,425 (62.1) | 1 (ref) | <0.001 | 1 (ref) | 0.009 |
| PLN1 (>0) | 870 (37.9) | 2.076 (1.722–2.502) | 1.999 (1.190–3.359) |
| LNR staging | | | | |
| LNR1 (=0) | 1,425 (62.1) | 1 (ref) | <0.001 | 1 (ref) | 0.009 |
| LNR2 (>0) | 870 (37.9) | 2.076 (1.722–2.502) | 1.999 (1.190–3.359) |
| LODDS staging | | | | |
| LODDS1 (≤–0.93) | 1,889 (81.4) | 1 (ref) | <0.001 | – | 0.317 |
| LODDS2 (>–0.93) | 426 (18.6) | 1.984 (1.636–2.405) |

^aAdjusted for age, sex, marriage, tumor location, extent of resection, histological grade, T staging, M staging, and the number of examined lymph nodes. No., number of patients; HR, hazard ratio.
The bold values means that the P value is less than 0.05.
Lymph Node Staging for PanNENs

The bold values means that the P value is less than 0.05.

The PLN staging (or 8th edition AJCC N staging) depends only on the number of PLNs; the impact of the number of examined lymph nodes (or negative lymph nodes) is not considered. When the number of PLNs is the same, patients with an insufficient number of examined lymph nodes might have a poorer prognosis; this phenomenon of understaging is called staging migration or Will Rogers phenomenon (20).

The LNR staging system may reduce the risk of the staging migration in some cancers, such as gastric cancers (21). However, the utility of the LNR is limited when the ratio value is zero. Another drawback is that patients with the same LNR count (e.g., 1/1 vs. 30/30) may have different prognoses. The optimal LNR cutoff in PanNENs is controversial and varies among studies, perhaps due to differences in the end points or protective factor when the number of PLNs is zero. In addition, restricted cubic spline functions indicate that LODDS is neither a risk factor nor a protective factor when the number of PLNs is zero.

The current study demonstrates that PLN staging performs better than LNR and LODDS staging for predicting cause-specific survival in patients with PanNENs after pancreatic resection surgery from both two-category and three-category perspective. Firstly, PLN and LNR staging, but not LODDS staging, were independent prognostic factors in the multivariate analysis. Secondly, PLN staging showed greater C-

**TABLE 5 | Survival analysis on the basis of two-category nodal staging schemes according to the number of examined lymph nodes (ELNs).**

| No. | PLN staging | LODDS staging | 1–5 ELNs | P<sub>b</sub> | 6–10 ELNs | P<sub>b</sub> | 11–15 ELNs | P<sub>b</sub> | 16–20 ELNs | P<sub>b</sub> | >20 ELNs | P<sub>b</sub> |
|-----|-------------|---------------|--------------|---------|--------------|---------|--------------|---------|--------------|---------|------------|---------|
| No. | Time | P<sub>b</sub> | No. | Time | P<sub>b</sub> | No. | Time | P<sub>b</sub> | No. | Time | P<sub>b</sub> | No. | Time | P<sub>b</sub> |
| PLN1 | 512 | 169.4 | 0.424 | 356 | 168.6 | 0.650 | 249 | 163.1 | 0.782 | 149 | 166.9 | 0.731 | 159 | 163.1 | 0.782 |
| PLN2 | 189 | 125.6 | 0.070 | 191 | 143.0 | 0.042 | 190 | 138.7 | 0.141 | 130 | 104.7 | 0.170 | 180 | 125.4 | 0.249 |
| LODDS1 | 532 | 168.2 | 0.018 | 443 | 172.3 | <0.001 | 356 | 170.6 | 0.020 | 237 | 143.7 | 0.176 | 301 | 154.5 | 0.013 |
| LODDS2 | 169 | 125.4 | <0.001 | 104 | 117.5 | 0.013 | 73 | 112.4 | 0.101 | 42 | 106.9 | 0.039 | 38 | 58.3 | 0.008 |

*Comparison of survival with group of >20 examined lymph nodes.

 обучения
index and AUC values than the LNR and LODDS staging systems, corresponding to better discriminatory capacity. Thirdly, and most importantly, no significant differences in survival were observed among patients in the same PLN staging subgroup according to the examined lymph node value (high or low). On the contrary, LNR and LODDS systems showed intra-group heterogeneity due to overestimating the risk of an insufficient number of examined lymph nodes. In consideration of the relatively good prognosis and limited prognostic value of lymph node metastasis in the patients with PanNENs, the ratio lymph nodal staging schemes (LNR and LODDS) designed to reduce intra-group heterogeneity was actually counterproductive.

The current study had some inherent limitations associated with the inherent limitations of the SEER database. For example, the SEER database does not include several important prognostic factors, such as patients’ symptoms, margin status, and chemotherapy, which may have affected the results of our Cox multivariate analysis. In addition, we excluded patients with missing data on the number of positive lymph nodes and examined lymph nodes, which may have caused selection bias. However, these are common shortcomings of retrospective and population-based studies. Given the rarity of PanNENs, retrospective studies based on large cancer registries are still of great significance, and prospective studies are needed to validate our conclusions.

In conclusion, the predictive value of the PLN staging system was not affected by an insufficient number of examined lymph nodes, while use of the LNR and LODDS systems was associated with an increased risk of nodal staging migration. The LODDS system did not stratify node-negative patients in terms of risk. Currently, the PLN staging (or 8th edition AJCC N staging) is superior to the LNR and LODDS staging.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://seer.cancer.gov/data/.

AUTHOR CONTRIBUTIONS

BG and DZ conceived the study. BG, ZL, XQ, WZ, and YJ collected and analyzed data. BG, DZ, and ZL wrote the manuscript. WW revised it critically. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (no. 81572307 and 81773096) and the Major Project of Medical and Health Technology Development Program in Zhejiang Province (No. 7211902).

REFERENCES

1. Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th edn. Lyon: IARC Press (2017).
2. Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer (2015) 121(4):589–97. doi: 10.1002/cncr.29099
3. Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol (2018) 47(2):1–10. doi: 10.1093/ije/dyx232
4. Amin MB, Edge SB. AJCC cancer staging manual. 8th ed. New York (NY): Springer (2017).
5. Partelli S, Javed AA, Andreasi V, He J, Muffatti F, MJ W, et al. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. Eur J Surg Oncol (2018) 44 (6):778–83. doi: 10.1016/j.ejso.2018.03.005
6. Siddell MB, Chang DC, Cameroen JL, Wolfgang C, Herman JM, Schulick RD, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol (2008) 15(1):165–74. doi: 10.1245/s10434-007-9587-1
7. Partelli S, Fernandez-Del Castillo C, Bassi C, Mantovani W, Thayer SP, Crippa S, et al. Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg (2010) 251(3):477–82. doi: 10.1097/SLA.0b013e3181ee9155
8. Gaitanidis A, Patel D, Nilabol N, Tyros A, Kebebew E. A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab (2018) 103(1):187–95. doi: 10.1207/s1j1cett187719
9. Vinh-Hung V, Vercschaeghen C, Promish DL, Cserni G, Van de Steene J, Tai P, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res (2004) 6(6):R680–8. doi: 10.1210/jc.2001-01791
10. Jiang SJ, Zhao LH, Xie CY, Su HF, Yan Y. Prognostic performance of different lymph node staging systems in patients with small bowel neuroendocrine Tumors. Front Endocrinol (Lausanne) (2020) 11:402. doi: 10.3389/fendo.2020.00402
11. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed (1997) 54(3):201–8. doi: 10.1016/0169-2607(97)00043-6
12. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 10(21):7252–9. doi: 10.1158/1078-0432.CCR-04-0713
13. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 15(4):361–87. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM1683>3.0.CO;2-4
14. Kamarudin AN, Cox T, Kalamunngaye-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol (2017) 17(1):53. doi: 10.1186/s12874-017-0332-6
15. Hashim YM, Trinkaus KM, Linehan DC, Straub SS, Fields RC, Cao D, et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg (2014) 259(2):197–203. doi: 10.1097/SLA.0000000000000348
16. Tanaka M, Heckler M, Mihaljevic AL, Probst P, Kläber U, Hegel U, et al. Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors. Ann Surg Oncol (2020). doi: 10.1245/ s10434-020-08850-7
17. Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th ed. New York (NY: Springer (2010).
18. Rindi G, Klopdel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2006) 449(4):395–401. doi: 10.1007/s00428-006-0250-1
19. Rindi G, Falconi M, Klersy C, Alberello L, Boninsegna L, Buchler MW, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large
international cohort study. *J Natl Cancer Inst* (2012) 104(10):764–77. doi: 10.1093/jnci/djs208

20. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. *N Engl J Med* (1985) 312(25):1604–8. doi: 10.1056/NEJM198506203122504

21. Sun Z, Zhu GL, Lu C, Guo PT, Huang BJ, Li K, et al. The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients. *Ann Oncol* (2009) 20(5):897–905. doi: 10.1093/annonc/mdn707

22. Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. *Eur J Cancer* (2012) 48 (11):1608–15. doi: 10.1016/j.ejca.2011.10.036

23. Ricci C, Casadei R, Taffurelli G, Buscemi S, D’Ambra M, Monari F, et al. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. *Pancreatology* (2013) 13(6):589–93. doi: 10.1016/j.pan.2013.09.001

24. Liu P, Zhang X, Shang Y, Lu L, Cao F, Sun M, et al. Lymph node ratio, but not the total number of examined lymph nodes or lymph node metastasis, is a predictor of overall survival for pancreatic neuroendocrine neoplasms after surgical resection. *Oncotarget* (2017) 8(31):49245–55. doi: 10.18632/oncotarget.19184

25. Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, et al. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. *Br J Cancer* (2017) 117 (12):1874–82. doi: 10.1038/bjc.2017.349

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Gao, Zhou, Qian, Jiang, Liu, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.